Related Experiment Video
Updated: Jun 18, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease
Tomoyuki Uchiyama1, Ryuji Sakakibara, Tatsuya Yamamoto
1Department of Neurology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan. uchiyama@faculty.chiba-u.jp
Movement Disorders : Official Journal of the Movement Disorder Society
|November 13, 2009
Summary
Bromocriptine and L-dopa worsen urinary urgency in Parkinson's disease (PD) patients. Both drugs improve bladder emptying, but bromocriptine's effects on bladder outlet obstruction differ from L-dopa.
Area of Science:
- Neurology
- Urology
- Pharmacology
Background:
- Parkinson's disease (PD) frequently causes lower urinary tract symptoms.
- Understanding the effects of PD medications on bladder function is crucial for patient management.
Purpose of the Study:
- To evaluate the impact of bromocriptine on bladder function in PD patients.
- To compare these effects with those of L-dopa.
Main Methods:
- Eight PD patients underwent urodynamic studies (UDS).
- UDS was performed before and after administration of bromocriptine and L-dopa/decarboxylase inhibitor (DCI).
Main Results:
- Bromocriptine exacerbated urinary urgency and detrusor overactivity (DO) during bladder filling.
- Bromocriptine improved bladder emptying by increasing detrusor contractility and decreasing bladder outlet obstruction.
- L-dopa also aggravated urgency and DO but had different effects on bladder outlet obstruction compared to bromocriptine.
Conclusions:
- Bromocriptine can worsen storage symptoms (urgency, DO) in PD patients.
- Bromocriptine aids bladder emptying, similar to L-dopa, but with some distinct effects on outlet resistance.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...